Drugs / JNT-517
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07713758 | Jul 2026 → Feb 2027 expected | phenylketonuria | Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07446400 | Mar → Jun 2026 overdue | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07573449 | Jan 2024 → Jan 2025 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05781399 | Oct 2022 → Jul 2025 | phenylketonuria | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06637514 | Jul 2025 → May 2026 | phenylketonuria | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06971731 | Oct 2025 → Mar 2028 expected | phenylketonuria | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06628128 | Aug 2025 → Nov 2027 expected | phenylketonuria | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting otsuka.co.jp ↗ |
| 2026-03-12 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting otsuka-us.com ↗ |
| 2025-12-19 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Initiates Global Phase 3 Clinical Trial Evaluating Repinatrabit for the Treatment of Phenylketonuria (PKU) otsuka.co.jp ↗ |
| 2025-12-19 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Initiates Global Phase 3 Clinical Trial Evaluating Repinatrabit for the Treatment of Phenylketonuria (PKU) otsuka-us.com ↗ |
| 2024-08-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.- Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) - - Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies - otsuka.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNT-517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05781399 ↗ |
| Known as | Repinatrabit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07446400 ↗ |
| Route | Oral | “oral JNT-517” NCT05781399 ↗ |